Is adalimumab effective in long-term real life clinical practice in both luminal and perianal Crohn 's disease . The Madrid experience?
Adalimumab is effective and safe for the management of CD, even in refractory cases to infliximab.
Our data suggest that PN is a promising biomarker for identifying individuals with poor prognostic potential and suggests its possible use as a prognostic marker in patients with osteosarcoma.